| |
 home
about us
science
news & publications
careers
contact us
|
|
 |
 |
| |
FoldRx is a leader in the discovery and development of first in class disease modifying drug therapies for diseases of protein misfolding and amyloidosis. |
|
- FoldRx Technology Enables Discovery of Novel Therapeutic Approach for Treating Cystic Fibrosis
July 8, 2008
- FoldRx and Cystic Fibrosis Foundation Therapeutics announce $22 million collaboration
August 13, 2007
- FoldRx Announces its Phase II/III Clinical Study with Lead Clinical Candidate
May 29, 2007
- FoldRx announces study defining role of key protein and biological pathway implicated in Parkinson's disease
June 22, 2006
- FoldRx Pharmaceuticals closes $43 Million Series B financing
May 30, 2006
- FoldRx announces the initiation of a Phase 1 study with First Clinical Candidate
October 12, 2005
- FoldRx Pharmaceuticals, Inc. appoints Christoph M. Adams, Ph.D., as Chief Business Officer
September 27, 2005
- FoldRx Pharmaceuticals, Inc. Closes on $16 Million Series A Round of Funding
December 13, 2004
Home | About Us | Science | News & Publications | Careers | Contact
© 2003-2007. FoldRx Pharmaceuticals, Inc. All Rights Reserved.
|
|
